Na Jenụwarị 29, 2025, otu ndị nyocha China bipụtara otu isiokwu akpọrọ "Neoadjuvant pyrotinib na trastuzumab na ọrịa kansa ara HER2 dị mma na-enweghị nzaghachi mbụ (NeoPaTHer): irè, nchekwa, na nyocha biomarker nke ọmụmụ ihe a na-atụ anya ya, nke nwere ọtụtụ ebe, nke a na-emegharị nzaghachi" na akwụkwọ akụkọ "Signal Transduction and Targeted Therapy".
A maara kansa ara nke nwere ihe nnabata epidermal growth factor 2 (HER2) nke mmadụ, nke bụ ihe ruru pasentị 15 ruo 25 nke kansa ara niile, dị ka ụdị dị iche na nke siri ike. A na-amata ya site na oke mmụba nke HER2, ihe nnabata transmembrane tyrosine kinase nke na-akwalite mmụba na ndụ nke mkpụrụ ndụ kansa. Ndị ọrịa nwere kansa ara nke nwere HER2 nwere ihe egwu dị elu nke nlọghachi na ọnwụ ma e jiri ya tụnyere ndị nwere ụdị kansa ara ndị ọzọ, na-eme ka ọ bụrụ ọrịa siri ike ịgwọ. Agbanyeghị, ọdịdị nke ọgwụgwọ kansa ara nke nwere HER2 nwere mgbanwe dị egwu n'ime afọ iri abụọ gara aga, nke bụ isi n'ihi mmalite nke ọgwụgwọ HER2 lekwasịrị anya. Karịsịa, mmalite nke trastuzumab agbanweela ụzọ nke kansa ara nke nwere HER2 site na ọrịa dị oke egwu gaa na nke nwere nsonaazụ ka mma na nke na-adịghị njọ.
N'agbata Ọktoba 2020 na Maachị 2022, e debanyere aha ndị ọrịa 129 sitere n'ụlọ ọgwụ ise na nnyocha a. N'ime ndị ọrịa 129 e debanyere aha, a chọpụtara 62 (48.1%) dị ka ndị na-aza MRI (cohort A), 26 na-azaghị ajụjụ gara n'ihu na usoro TCbH anọ ọzọ (cohort B), na 41 na-azaghị ajụjụ natara pyrotinib ọzọ (cohort C). Ọnụego tpCR bụ 30.6% (95% CI: 20.6–43.0%) na otu A, 15.4% (95% CI: 6.2–33.5%) na otu B, na 29.3% (95% CI: 17.6–44.5%) na otu C. Nnyocha mgbanwe logistic dị iche iche gosipụtara ohere yiri nke iru tpCR n'etiti otu A na C (nha nha = 1.04, 95% CI: 0.40–2.70). Ahụghị ihe ọjọọ ọhụrụ ọ bụla na mgbakwunye nke pyrotinib. Ndị ọrịa nwere mgbanwe co-motion nke TP53 na PIK3CA gosipụtara ọnụego dị ala nke nzaghachi akụkụ mbụ ma e jiri ya tụnyere ndị na-enweghị ma ọ bụ nwere otu mkpụrụ ndụ ihe nketa (36.0% vs. 60.0%, P = 0.08). Nchọpụta ndị a na-egosi na itinye pyrotinib nwere ike ịba uru nye ndị ọrịa na-anaghị anabata neoadjuvant trastuzumab plus chemotherapy. Nnyocha ọzọ dị mkpa iji chọpụta ihe ndị na-egosi uru ndị ọrịa ga-erite site na mgbakwunye nke pyrotinib.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Ntụaka
https://www.nature.com/articles/s41392-025-02138-6
Oge ozi: Feb-08-2025